LANGHORNE, PA — NEXGEL, Inc. (NASDAQ: NXGL) said its planned spin-off, NexGelRx, has secured strategic investments from Eric Gruntfest and Ariel Imas of Diesis Holdings, a move aimed at strengthening the venture’s commercialization and reimbursement strategy.
As part of the investment, NexGelRx appointed Gruntfest as a board observer and advisor, adding senior-level expertise in payer access, reimbursement frameworks, and healthcare commercialization. The appointment signals an early emphasis on market access as the company advances drug delivery applications built around its hydrogel technology.
Gruntfest brings more than two decades of experience across reimbursement management and patient support programs. He is managing partner of Diesis Holdings and chief executive officer of RMBB Health, with prior leadership roles at Medtronic, MiMedx, Shire, and Celgene. His background includes building payer strategies and scaling patient access initiatives across complex healthcare markets.
NexGelRx is the drug delivery-focused spin-off of NEXGEL, which has been repositioning parts of its portfolio to highlight applications beyond wound care. The company is developing an ultra-gentle hydrogel platform designed for transdermal delivery, targeting pharmaceutical uses that require localized, patient-friendly administration.
Management said the investment broadens NexGelRx’s stakeholder base while aligning the company with partners experienced in navigating reimbursement and adoption hurdles that often determine commercial success in healthcare.
For NEXGEL, the transaction advances its strategy of unlocking value through focused entities, while giving NexGelRx early backing from investors with deep operational and market-access credentials.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.